- Conditions
- Appendix Cancer, Colorectal Cancer
- Interventions
- Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 9
- States / cities
- Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer Debulking, Enlarged Uterus, Fibroid Uterus, Adnexal Mass
- Interventions
- Bupivacaine, Morphine, Lidocaine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cancer Patients Receiving Stereotactic Body RTX
- Interventions
- SBRT
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Malignant Neoplasm of Ovary, Malignant Neoplasm of Fallopian Tube, Malignant Neoplasm of Peritoneum
- Interventions
- Diagnostic laparoscopy
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Cleveland, Ohio
- Conditions
- Gastrointestinal Neoplasm
- Interventions
- Cytoreductive surgery, Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
- Interventions
- neoadjuvant chemotherapy
- Drug
- Lead sponsor
- Rachel Miller
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Pituitary Adenoma
- Interventions
- Octreotide LAR, transsphenoidal surgery
- Drug · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
- Interventions
- Oregovomab, Paclitaxel, Carboplatin, Placebo
- Biological · Drug
- Lead sponsor
- CanariaBio Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
- Conditions
- High Grade Glioma
- Interventions
- Trans Sodium Crocetinate (TSC)
- Drug
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Interventions
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 60 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Obinutuzumab, Bendamustine, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 15
- States / cities
- Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- adjuvant therapy, paclitaxel, carboplatin, bevacizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 17
- States / cities
- Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more
- Conditions
- Ovarian Cancer
- Interventions
- filgrastim, carmustine, cisplatin, melphalan, paclitaxel, peripheral blood stem cell transplantation, surgical procedure
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ovarian Neoplasms
- Interventions
- Niraparib, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- San Francisco, California • Miami, Florida • Tampa, Florida + 7 more
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone, Positron Emission Tomography (PET), Blood specimen collection, Questionnaires, Computerized tomography (CT)
- Drug · Procedure · Behavioral
- Lead sponsor
- Mwanasha Merrill, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Malignant Mesothelioma
- Interventions
- recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 3
- States / cities
- Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
- Conditions
- Peritoneal Neoplasms
- Interventions
- Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
- Procedure · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Glioblastoma, Brain Tumor
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Interventions
- HDMP + rituximab as a means of debulking prior to initiating venetoclax.
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Alvimopan, Placebo
- Drug
- Lead sponsor
- Jamie N. Bakkum-Gamez
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ovarian Cancer
- Interventions
- cisplatin
- Drug
- Lead sponsor
- The Netherlands Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • New York, New York
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
- Interventions
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer
- Interventions
- Radspherin
- Drug
- Lead sponsor
- Oncoinvent Solutions AS
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Renal Cancer
- Interventions
- Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- Biological · Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts